QUOIN PHARMACEUTICALS LT-ADR (QNRX) Stock Overview
USA - NASDAQ:QNRX - US74907L4095 - ADR
QNRX Key Statistics, Chart & Performance
The current stock price of QNRX is 13.25 USD. In the past month the price increased by 77.85%. In the past year, price decreased by -54.21%.
QNRX Latest News, Press Relases and Analysis
QNRX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 21.46 | 401.47B | ||
| AMGN | AMGEN INC | 13.27 | 155.84B | ||
| GILD | GILEAD SCIENCES INC | 15.55 | 149.34B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.88 | 108.08B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.76 | 61.72B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 63.13B | ||
| ARGX | ARGENX SE - ADR | 90.1 | 51.09B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.1 | 34.67B | ||
| INSM | INSMED INC | N/A | 34.50B | ||
| NTRA | NATERA INC | N/A | 26.30B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.38B | ||
| BIIB | BIOGEN INC | 9.36 | 21.96B |
Related stock screener links
About QNRX
Company Profile
Quoin Pharmaceuticals Ltd. engages in the development of therapeutic products for the treatment of rare and orphan diseases. The Company’s first lead product is QRX003, a once daily, topical lotion comprised of a broad-spectrum serine protease inhibitor, formulated with the proprietary Invisicare technology, to treat Netherton Syndrome. The product going to be developed for other rare dermatological diseases including Peeling Skin Syndrome, SAM Syndrome, and Palmoplantar Keratoderma. Quoin is also developing QRX004 as a potential treatment for Dystrophic Epidermolysis Bullosa, and QRX006 as a potential therapy for an, as of yet, undisclosed rare skin disease.
Company Info
QUOIN PHARMACEUTICALS LT-ADR
23 Hata'as Street
Kfar Saba IL
CEO: Shai Yarkoni
Employees: 4
Phone: 97299741444
QUOIN PHARMACEUTICALS LT-ADR / QNRX FAQ
What does QUOIN PHARMACEUTICALS LT-ADR do?
Quoin Pharmaceuticals Ltd. engages in the development of therapeutic products for the treatment of rare and orphan diseases. The Company’s first lead product is QRX003, a once daily, topical lotion comprised of a broad-spectrum serine protease inhibitor, formulated with the proprietary Invisicare technology, to treat Netherton Syndrome. The product going to be developed for other rare dermatological diseases including Peeling Skin Syndrome, SAM Syndrome, and Palmoplantar Keratoderma. Quoin is also developing QRX004 as a potential treatment for Dystrophic Epidermolysis Bullosa, and QRX006 as a potential therapy for an, as of yet, undisclosed rare skin disease.
What is the stock price of QUOIN PHARMACEUTICALS LT-ADR today?
The current stock price of QNRX is 13.25 USD. The price increased by 2.32% in the last trading session.
What is the dividend status of QUOIN PHARMACEUTICALS LT-ADR?
QNRX does not pay a dividend.
What is the ChartMill rating of QUOIN PHARMACEUTICALS LT-ADR stock?
QNRX has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
What is the employee count for QNRX stock?
QUOIN PHARMACEUTICALS LT-ADR (QNRX) currently has 4 employees.
What is QUOIN PHARMACEUTICALS LT-ADR worth?
QUOIN PHARMACEUTICALS LT-ADR (QNRX) has a market capitalization of 7.79M USD. This makes QNRX a Nano Cap stock.
What is the ownership structure of QUOIN PHARMACEUTICALS LT-ADR (QNRX)?
You can find the ownership structure of QUOIN PHARMACEUTICALS LT-ADR (QNRX) on the Ownership tab.
QNRX Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to QNRX. When comparing the yearly performance of all stocks, QNRX turns out to be only a medium performer in the overall market: it outperformed 44.88% of all stocks.
QNRX Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to QNRX. Both the profitability and financial health of QNRX have multiple concerns.
QNRX Financial Highlights
Over the last trailing twelve months QNRX reported a non-GAAP Earnings per Share(EPS) of -41.48. The EPS increased by 78.57% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -136.54% | ||
| ROE | -476.97% | ||
| Debt/Equity | 1.03 |
QNRX Forecast & Estimates
8 analysts have analysed QNRX and the average price target is 28.05 USD. This implies a price increase of 111.7% is expected in the next year compared to the current price of 13.25.